REDEFINE 4 was an 84-week open-label Phase 3 study in 809 adults with obesity and at least one comorbidity, with a mean baseline weight of 114.2 kg
Early evidence and clinical experience suggest they may be powerful adjuncts for recovery, longevity, and optimization helping patients heal faster, age gracefully, and perform at their best.
Teams reviewing this SKU often compare carrier peptide, mineral delivery support, skin conditioning support alongside factors such as water-soluble, strong stability in solution, widely studied peptide complex when building formulation-development, sourcing, validation, and repeat-order shortlists for more serious technical, wellness-adjacent, and commercially credible peptide portfolios
GDC treated monolayers were biocompatible with infant formula digesta and resulted in higher concentrations of bioavailable amino acids ( P 3.0.CO;2-6 11